Athmar Dhahir Habeeb

Athmar Dhahir Habeeb

Auto-generated profile, based on publicly available information

Athmar Dhahir Habeeb

Mustansiriyah University, Baghdad, Iraq

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2017 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
SASahar Awwad
Sahar Awwad
AAAthmar Al‐Shohani
Athmar Al‐Shohani
PKPeng T. Khaw
Peng T. Khaw
SBSteve Brocchini
Steve Brocchini

14 May 2025 in Pharmacia
Verified
Journal Article
Open access
PDF file
SMSarah Sabah Muter
Sarah Sabah Muter
AHAthmar Dhahir Habeeb
Athmar Dhahir Habeeb
Baclofen, a muscle relaxant used for severe pain management, has a narrow absorption window limiting its bioavailability. Enhancing its gastric residence time could potentially improve its absorption and effectiveness. Floating drug delivery systems are a promising approach to prolong drug retention in the stomach. This study aimed to develop a floating bilayer film for the sustained release of baclofen. The core of the film was formulated with baclofen, PVP K90, sodium alginate, and PEG 400 as a plasticizer, while the controlled release layer contained Eudragit RS100 or RLPO with different plasticizers (DBP and PEG 400). All formulations were evaluated for weight uniformity, drug content, thickness, folding ability, swelling, and in vitro drug release. The optimized formula had a 98% drug release within 12 hours, floated effectively for 24 hours, and followed zero-order kinetics.

1 February 2018 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
ASAshti M H Saeed
Ashti M H Saeed
MAMaryam H Alaayedi
Maryam H Alaayedi
AAAthmar Dh H Alshohani
Athmar Dh H Alshohani
Objective: The objective of our current work is to formulate, optimize and evaluate new combination rectal suppositories as a treatment for rheumatoid arthritis that contains both lornoxicam and aloin. Both are strong anti-inflammatory agents, and a combination of both may have synergistic effect as an anti-inflammatory treatment.Methods: Rectal suppositories containing 8 mg lornoxicam and 200 mg aloin were formulated by heat fusion method. Different combinations of different molecular weights of polyethylene glycol (PEG) were used for the formulated suppositories. The formulated suppositories were evaluated for their visual appearance, weight variation, hardness, friability, disintegration time, melting temperature, and drug content uniformity.Results: All the formulations prepared were within the required limits for USP. When the release study was performed, both drugs were released from all the formulations prepared. However, formulation F7 which is composed of PEG 400 30.88% (w/w): PEG 4000 46.32% (w/w) was superior to other formulations in which more than 80% of both drugs loaded were released after 35 min. The presence of both drugs in the same suppository did not affect their release.Conclusion: A new combination suppositories have been obtained where the two combined drugs were released fast without interference with each other release. The proposed new combination has the potential to be used as a strong analgesic and anti-inflammatory treatment compared to using lornoxicam or aloin alone.